Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“2025 Reflections – Here’s what stood out.
On a recent flight long haul flight, I reflected on our work in US Oncology at AstraZeneca. It’s been a year of meaningful progress, steady momentum and learning – both professionally and personally.
Highlights from 2025 (in no particular order)
1. ASCO Plenary, again: Taking the ASCO plenary stage for the seventh straight year bringing progress and hope to patients .
2. Scaling cell therapy: Opening a new manufacturing site in Rockville, MD to accelerate next‑gen modalities for patients.
3. Regulatory wins: Achieving seven FDA approvals for our cancer medicines that helps turn science into standards of care.
4. Data that matters: Delivering ten positive phase 3 trial readouts, including five in breast cancer across stages and subtypes.
5. Global stages: Presenting three Presidential Symposiums across ESMO and WCLC, elevating practice‑changing evidence.
6. Building for the future: Breaking ground on a new facility in Albemarle County near Charlottesville, VA.
7. Patient impact: Touching the lives of thousands of cancer patients in the US this year
8. Policy progress: Passing of The ORPHAN Cures Act, protecting rare disease innovation that patients rely on.
9. Growing our team: Welcoming hundreds of new colleagues to US Oncology.
10. Personal reset: Cherished time with family in India. If you can, unplug this holiday season. It’s worth it.
I’d love to hear a highlight from your year in the comments.
Thank you to the many cross-functional teams, partners and individuals who make this possible. None of this happens without shared passion and collaboration.
With gratitude – until next year,
Mohit”
More posts featuring Mohit Manrao.